Small companies adapt to the exo model more naturally than large organizations because they lack immune system antibodies; small startups can jump to new exo models directly, while legacy firms (using 50 years of MBA thinking) must unlearn old paradigms; emerging markets are hungrier and more flexible than Western incumbents.